American drug regulators have refused to approve one of the most closely watched medicines ever developed in China, a setback for the country’s ambition to produce a globally dominant cancer treatment. The drug, ivonescimab, was developed by the Chinese biotech Akeso and licensed in North America by the U.S. firm Summit Therapeutics.
Ivonescimab is a bispecific antibody, a single engineered protein that blocks two targets at once: PD-1, the molecular brake that stops immune cells from attacking tumors, and VEGF, a signal tumors use to grow new blood vessels. Analysts have seen the combination as a potential challenger to Merck’s Keytruda, the world’s bestselling cancer drug, because attacking both pathways at once may work better than unlocking the immune system alone.
The U.S. Food and Drug Administration issued what is called a complete response letter, meaning the application cannot be approved in its current form. The agency’s objection was not about manufacturing or safety. It said the company had not established effectiveness because the pivotal trial, HARMONi, failed to show a statistically significant improvement in overall survival — whether patients actually lived longer. The trial did meet its other main goal. On ivonescimab plus chemotherapy, patients with a hard-to-treat form of advanced lung cancer went a median 6.8 months without their disease worsening, against 4.4 months on chemotherapy alone, cutting the risk of progression or death by nearly half. But at the primary analysis the survival benefit was a positive trend that narrowly missed the cutoff for statistical significance, with a p-value of 0.057. The FDA concluded that delaying tumor growth without proving longer life was not enough to support approval.
The decision carries weight beyond one drug. Ivonescimab was approved in China in 2024 for the same lung-cancer indication and is seen by international investors as a test case for whether Chinese clinical-trial data, much of it collected at Chinese hospitals, can satisfy American reviewers. Roughly half the patients in earlier studies were Chinese, and Summit had argued that the survival data were simply less mature among Western patients; later follow-up showed the two groups converging, with about a 24 percent reduction in the risk of death. The rejection also reflects a broader shift at the FDA toward demanding survival gains in cancer trials, especially for patients who have other options, rather than accepting delayed progression as proof. Drug companies around the world are developing dozens of similar PD-1/VEGF combinations, and the letter is expected to push all of them toward larger and longer trials.
Summit said it was disappointed for patients and would review the letter with the agency. Akeso’s broader program continues, including a first-line trial that offers another path into the American market. For China’s fast-maturing drug industry, the message is that scientific ingenuity alone no longer settles the argument — American approval now demands the most rigorous evidence a cancer trial can produce.

Dgcity